fog pharma
Parabilis Medicines is a clinical-stage biopharmaceutical company developing Helicon peptide therapeutics to address historically undruggable cancer targets, with lead candidate zolucatetide in Phase 1/2 trials for Wnt/b-catenin-driven solid tumors.
- Company typePublic
- Founded2015
- HeadquartersCambridge, United States
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What fog pharma does
Parabilis Medicines (Nasdaq: PBLS), formerly Fog Pharma, is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts. The company develops stabilized helical peptides — branded as Helicons — engineered to penetrate cells and bind flat intracellular protein surfaces, addressing the approximately 80% of biologically validated disease targets considered historically undruggable by conventional small molecules and antibodies. Its lead product candidate, zolucatetide (formerly FOG-001), is the first drug to directly target the b-catenin:TCF interaction in the Wnt/b-catenin pathway and is currently in Phase 1/2 clinical trials for desmoid tumors and other solid tumors driven by Wnt/b-catenin pathway alterations. As of February 2026, the company has dosed over 150 patients and reported a 74% objective response rate (14/19 patients) and 100% disease control rate (25/25 evaluable patients) in the desmoid tumor cohort, with a Phase 3 registrational trial planned for H1 2027.
The company operates a vertically integrated R&D engine that combines AI- and physics-based computational modeling with mRNA display, high-throughput peptide synthesis, and experimental screening, all refined by a decade of proprietary datasets. Two preclinical programs (ERG and ARON) extend the platform into prostate cancer. Parabilis is pre-revenue, with no approved products, and intends to commercialize zolucatetide upon regulatory approval through specialty pharmacy and hospital formulary channels targeting oncologists and specialty physicians primarily in the United States. The company maintains a wholly-owned subsidiary in Shanghai, Parabilis Medicines (Shanghai) Ltd Co, and a domestic subsidiary, Parabilis Security Corporation.
In June 2026, Parabilis completed an upsized IPO on the Nasdaq Global Select Market, raising $770.5 million in gross proceeds at $20.00 per share, alongside a concurrent $75 million private placement to Regeneron Pharmaceuticals that deepened an existing strategic research collaboration. Total capital raised across 2026 exceeded $1.2 billion. The company is led by CEO, President and Chairman Mathai Mammen, M.D., Ph.D., with a board representing institutional investors including RA Capital and Deerfield Management.
fog pharma firmographics
Firmographics- Name
- fog pharma
- Legal name
- Parabilis Medicines, Inc.
- Website
- https://fogpharma.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Short description
- Parabilis Medicines is a clinical-stage biopharmaceutical company developing Helicon peptide therapeutics to address historically undruggable cancer targets, with lead candidate zolucatetide in Phase 1/2 trials for Wnt/b-catenin-driven solid tumors.
- Ownership category
- akta.pro rank
fog pharma industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)
Keywords
Where fog pharma is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
fog pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pipeline Drug Development and Commercialization: Pre-revenue clinical-stage company developing novel Helicon-based therapeutics. Currently has no approved products. Revenue will come from commercialization of drug candidates upon regulatory approval, initially focusing on zolucatetide for desmoid tumors and expanding to additional oncology indications.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
fog pharma product offering
Product offeringCore offering
Parabilis Medicines is a clinical-stage biopharmaceutical company developing peptide-based therapeutics built on its proprietary Helicon peptide platform. Its lead product candidate, zolucatetide, is the first drug designed to directly target the beta-catenin:TCF interaction in the Wnt/beta-catenin pathway and is being evaluated in Phase 1/2 clinical trials for desmoid tumors and other solid tumors. The company also maintains preclinical programs (ERG, ARON) targeting historically undruggable drivers of prostate cancer.
Product overview
Parabilis Medicines is a clinical-stage biopharmaceutical company developing medicines based on its proprietary Helicon platform. The core offering is zolucatetide (formerly FOG-001), the lead product candidate and first-in-industry Helicon therapeutic targeting the beta-catenin:TCF interaction. The company operates two key programs: the Helicon discovery platform (integrating AI and computational modeling) and its pipeline of Helicon-based product candidates. Preclinical programs include ERG and ARON targeting prostate cancer. The company completed its IPO in June 2026 and trades on Nasdaq under ticker PBLS.
Differentiator
Problem solved
Functional benefit
Brands
- Helicon: Ultra-tunable Helicon peptide platform technology - stabilized helical peptides engineered to bind and precisely modulate historically undruggable protein targets.
- Zolucatetide
Products and services
- Zolucatetide
- ERG Program
- ARON Program
Quantifiable outcome
- 74% objective response rate (ORR) in desmoid tumor patients with at least two post-baseline scans (14/19 patients per RECIST 1.1)
- +3 more outcomes
Companies that use fog pharma
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
fog pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature5 records
fog pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Regeneron Pharmaceuticals, Inc.majorParabilis entered into a strategic research collaboration with Regeneron. In connection with the collaboration, Regeneron agreed to purchase approximately $75 million of shares in a concurrent private placement at the IPO. The relationship extends beyond capital investment into ongoing research collaboration activities.
Scale indicators10 records
Recent moves8 records
Expansion highlights12 records
fog pharma competitors and assessment
Company assessmentDirect peers
- Arvinas: Arvinas is a clinical-stage biotech developing targeted protein degraders (PROTACs and related modalities) against historically undruggable oncology targets. It shares Parabilis's thesis of going after targets that small molecules cannot address and is at a similar clinical/commercial maturity stage.
- Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide therapeutics (a related peptide modality) targeting historically difficult intracellular and extracellular oncology targets. It is a directly comparable clinical-stage biotech using engineered constrained peptides to drug protein-protein interactions, with similar pipeline-stage profile.
- Relay Therapeutics: Relay Therapeutics is a clinical-stage precision oncology company using computational/motion-based drug design to target historically undruggable oncogenic drivers such as PI3Kα and KRAS. It shares Parabilis's integration of AI/computation with novel chemistry to address difficult oncology targets.
- Revolution Medicines: Revolution Medicines is a clinical-stage oncology biotech developing targeted therapies against difficult-to-drug RAS and other historically undruggable oncogenic drivers. It is a close peer given the shared focus on novel modalities tackling previously intractable targets in solid tumors.
- Tango Therapeutics: Tango Therapeutics is a clinical-stage precision oncology company developing synthetic lethality-based therapeutics. It is a directly comparable targeted-oncology biotech at a similar stage, sharing the thesis of exploiting cancer-specific vulnerabilities.
Emerging players
- Scholar Rock: Scholar Rock is a clinical-stage biotech developing biologics (including inhibitors of TGFβ and related growth factor pathways) for oncology and rare diseases. It is a relevant emerging peer targeting difficult signaling pathways with novel biologics modalities.
- Moderna: Moderna is a clinical-stage biotech whose mRNA platform intersects with Parabilis's use of mRNA display for peptide discovery. It is an emerging peer with overlapping protein engineering and computational biology capabilities, though its primary therapeutic focus is vaccines and gene therapy.
- Mirati Therapeutics (acquired by BMS): Mirati Therapeutics was a clinical-stage precision oncology biotech developing KRAS and other targeted oncology therapies before being acquired by Bristol-Myers Squibb. It represents a comparable targeted oncology company and an indicator of the strong M&A appetite in this space.
Broad incumbents
- Amgen (with several pipeline programs in Wnt signaling): Amgen is a major biopharmaceutical incumbent developing oncology biologics including Wnt-pathway and related targeted oncology programs. As a large established biopharma, it offers broader capabilities than Parabilis but overlaps in the targeted oncology space.
- Regeneron Pharmaceuticals: Regeneron is a major biopharma incumbent that has a strategic research collaboration and equity investment in Parabilis. While Regeneron operates across many therapeutic areas, its antibody and biologics capabilities and strategic interest in Parabilis make it a relevant comparable incumbent.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
fog pharma social profiles
Digital presencefog pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
fog pharma leadership team
Management profileNumber of profiles
Profiles12 records
fog pharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
fog pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
fog pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about fog pharma
What does fog pharma do?
Parabilis Medicines is a clinical-stage biopharmaceutical company developing peptide-based therapeutics built on its proprietary Helicon peptide platform. Its lead product candidate, zolucatetide, is the first drug designed to directly target the beta-catenin:TCF interaction in the Wnt/beta-catenin pathway and is being evaluated in Phase 1/2 clinical trials for desmoid tumors and other solid tumors. The company also maintains preclinical programs (ERG, ARON) targeting historically undruggable drivers of prostate cancer.
Is fog pharma a public or private company?
fog pharma is a public company. It is classified as public and is currently operating.
When was fog pharma founded?
fog pharma was founded in 2015.
Where is fog pharma based?
fog pharma is headquartered in Cambridge, United States, in the North America region.
How does fog pharma make money?
One revenue line is on record: pipeline Drug Development and Commercialization.
Who are fog pharma's main competitors?
Direct peers on record are Arvinas, Bicycle Therapeutics, Relay Therapeutics, Revolution Medicines and Tango Therapeutics. Emerging players are Scholar Rock, Moderna and Mirati Therapeutics (acquired by BMS). Broad incumbents are Amgen (with several pipeline programs in Wnt signaling) and Regeneron Pharmaceuticals.
Does fog pharma have an API?
No public API is recorded for fog pharma.
What industry is fog pharma in?
fog pharma's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325414 and its SIC code is 2834.